SARS CoV 2 News and Research

RSS

Clear and unequivocal evidence we should washing our hands during COVID-19

The study shows that Americans are washing their hands much more they did before the coronavirus pandemic. However, the groups who are less likely to remember to wash their hands on multiple occasions were white people, men, and those between the ages of 18 and 24.

9 Oct 2020

Mass production of SARS-CoV-2 ORF8 protein using a chemical-inducible system in tobacco BY-2 cells

Researchers from the Japan Advanced Institute of Science and Technology (JAIST) and Ishikawa Prefectural University, Japan, recently attempted to synthesize the ORF8 protein with the help of a chemical-inducible protein production system using tobacco BY-2 cells. This study has been published demonstrated in the preprint server, bioRxiv.

9 Oct 2020

Virginia Tech to build a cyberinfrastructure for wastewater antibiotic-resistant gene monitoring

Antibiotic resistance is a grand challenge of the 21st century. According to the U.S. Centers for Disease Control and Prevention, antibiotic resistance rates are increasing globally, with an estimated 35,000 related deaths per year in the United States in 2019, compared to 23,000 in 2013.

8 Oct 2020

Mount Sinai to receive more than $7.3 million as part of NCI's new Serological Sciences Network

Researchers from the Icahn School of Medicine at Mount Sinai will receive more than $7.3 million from the National Cancer Institute as part of the NCI's new Serological Sciences Network (SeroNet), one of the largest coordinated national efforts to study immunology and SARS-CoV-2, the virus that causes COVID-19.

8 Oct 2020

Certain pre-existing conditions may highly increase a patient's risk of dying from COVID-19

A large, international study of COVID-19 patients confirmed that cardiovascular disease, hypertension, diabetes, congestive heart failure, chronic kidney disease, stroke and cancer can increase a patient's risk of dying from the virus.

8 Oct 2020

NIH clinical trial to test a combination treatment regimen for COVID-19

A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, has begun.

8 Oct 2020

SARS-CoV-2 survives on human skin for 9 hours

Japanese researchers have now studied the survival possibilities of the flu virus and the SARS-CoV-2 on human skin. Their study titled, "Survival of SARS-CoV-2 and influenza virus on the human skin: Importance of hand hygiene in COVID-19," was published in the latest issue of the journal Clinical Infectious Diseases.

8 Oct 2020

Detection of SARS-CoV-2 viral persistence in built environments

In a recent paper in an open-access journal, mSystems, published by The American Society for Microbiology, Ceth W. Parker et al. show challenges in recovering the virus, change in infectivity, and the case of viral persistence in built environments.

8 Oct 2020

Scientists refine SARS-CoV-2 protein structures

An international team of scientists has developed computational models to re-analyze and validate experimentally-derived publicly available macromolecular structures of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Oct 2020

Overreaction of the immune system could be linked to severe COVID-19 cases

Samples from the lungs of patients show a runaway immune system reaction could be one mechanism behind severe COVID-19 cases.

8 Oct 2020

Face masks far more protective against COVID-19 than face shields, CDC experts

Researchers from the Centers for Disease Control and Prevention (CDC) have conducted a study showing that face masks and neck gaiters appear to be much more effective than face shields at reducing the expulsion of respiratory aerosols that could potentially transmit severe acute respiratory syndrome 2 (SARS-CoV-2).

8 Oct 2020

Neutralizing responses to infection relatively common in COVID-19

A new study has shown that severe coronavirus disease 2019 (COVID-19) is associated with unique B cell receptor (BCR) signatures and multiclonal neutralizing responses against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Oct 2020

Leopoldina appeals to governments to take protective measures on COVID-19 pandemic

Since the end of July, the number of new infections with the coronavirus has been on the rise again in Germany.

8 Oct 2020

Researchers identify a promising method to stop COVID-19 infection

While the world waits eagerly for a safe and effective vaccine to prevent infections from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus behind the COVID-19 pandemic, researchers also are focusing on better understanding how SARS-CoV-2 attacks the body in the search for other means of stopping its devastating impact.

8 Oct 2020

Study: New viral mutations would not impact the efficacy of Covid-19 vaccine candidates

Vaccines currently being developed for Covid-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologist.

8 Oct 2020

The Native Antigen Company introduces ten new SARS-CoV-2 specific antibodies

The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the introduction of ten new monoclonal antibodies recognizing SARS-CoV-2, the causative agent of COVID-19.

8 Oct 2020

Pre-existing conditions can increase patient's risk of dying from COVID-19

8 Oct 2020

Study estimates lower herd immunity to SARS-CoV-2 in the U.S.

A new study shows that recognizing the differences in the population composition, connectedness and distribution, as well as inter-individual differences in immunity, susceptibility and infectivity, are crucial to estimating the herd immunity attained as a result of natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) more accurately.

8 Oct 2020

Comet supercomputer performs complex calculations on receptor sequence data from human T cells

While researchers around the world race to develop an effective and safe COVID-19 vaccine, a team from the San Diego Supercomputer Center (SDSC) at UC San Diego contributed to a study led by Vanderbilt Vaccine Center of Vanderbilt University Medical Center (VUMC) on T cell receptors, which play a vital role in alerting the adaptive immune system to mount an attack on invading foreign pathogens including the Coronavirus SARS-CoV-2.

8 Oct 2020

Vitamin D deficiency may predict COVID-19 seroconversion

A recent study published on the preprint server medRxiv* in October 2020 reports the potential contribution of vitamin D deficiency to an increased risk of COVID-19 in a subset of health care workers in the UK.

8 Oct 2020